Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

CDO1 Inhibitors

CDO1 inhibitors encompass a diverse and specialized chemical class of compounds meticulously developed to exert precise control over the enzymatic function of Cysteine Dioxygenase Type 1 (CDO1). Functioning as a pivotal enzyme within the intricate framework of cysteine metabolism, CDO1 plays a critical role in the oxidative degradation of cysteine. The inhibitors tailored for CDO1 operate by engaging with the enzyme's active site, where the native substrate, cysteine, typically binds during catalysis. This strategic interaction effectively disrupts the enzymatic cascade responsible for the conversion of cysteine to cysteine sulfinic acid. The rationale behind these inhibitors is rooted in their potential to serve as indispensable tools for investigating the intricate dynamics of cysteine metabolism modulation, unraveling the network of biochemical processes that hinge upon this amino acid.

In the realm of molecular design, the creation of CDO1 inhibitors involves an intricate interplay between structural insights into the enzyme's conformation and its intricate substrate-binding site. This approach, known as rational drug design, aims to engineer compounds that manifest a high degree of selectivity and potency, ensuring their affinity for CDO1 without encroaching upon other enzymatic systems. Crafting these inhibitors demands a meticulous analysis of their chemical architecture, encompassing considerations of molecular geometry, functional group arrangement, and stereochemistry. Such factors collectively influence the binding kinetics and inhibitory potential of the compounds, ultimately dictating their capacity to attenuate CDO1 activity. Through their targeted modulation of CDO1, this distinct class of inhibitors has emerged as an indispensable asset in the scientific arsenal, casting light upon the intricate regulatory mechanisms that underpin cysteine metabolism. By affording researchers the ability to finely manipulate CDO1 activity, these inhibitors lay the foundation for comprehensive investigations into the multifaceted roles of cysteine within diverse physiological and biochemical contexts.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Hydralazine-15N4 Hydrochloride

304-20-1 (unlabeled)sc-490605
1 mg
$480.00
(0)

Primarily used as an antihypertensive drug, hydralazine has been shown to inhibit CDO1 activity, potentially impacting cysteine metabolism.